PRESS RELEASE

Q3 2024 — Press release

Q3 2024PDF · 14 pages266 KB
News Release
____________________________________________________________________________
Merck Announces Third-Quarter 2024 Financial Results
- Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023;
Excluding the Impact of Foreign Exchange, Growth Was 7%
o KEYTRUDA Sales Grew 17% to $7.4 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 21%
o WINREVAIR Sales Were $149 Million; U.S. Launch of WINREVAIR Gaining
Momentum; Received Approval in the EU
o Animal Health Sales Grew 6% to $1.5 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 11%
- GAAP EPS Was $1.24; Non-GAAP EPS Was $1.57; GAAP and Non-GAAP EPS Include
a Net Charge of $0.79 per Share Related to Certain Business Development
Transactions
- Achieved Significant Milestones in Vaccine Programs
o CAPVAXIVE Recommended by the CDC’s ACIP for Pneumococcal Vaccination
in Adults 50 Years of Age and Older
o Presented Positive Results From Clinical Studies Evaluating Clesrovimab (MK-
1654), an Investigational RSV Preventative Monoclonal Antibody for Infants
Entering Their First RSV Season
- Data Presented for Four Approved Medicines and Six Pipeline Candidates in More Than
20 Types of Cancer at ESMO Congress 2024, Including Overall Survival Data From
KEYNOTE-522 and KEYNOTE-A18
- Completed Acquisition of Investigational B-Cell Depletion Therapy, CN201 (MK-1045),
From Curon Biopharmaceutical
- Full-Year 2024 Financial Outlook
o Narrows Expected Worldwide Sales Range To Be Between $63.6 Billion and
$64.1 Billion
o Now Expects Non-GAAP EPS To Be Between $7.72 and $7.77; Outlook Reflects
a Net Negative Impact of $0.24 per Share Related to Business Development
Transactions With Curon Biopharmaceutical and Daiichi Sankyo
RAHWAY, N.J., Oct. 31, 2024 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the third quarter of 2024.
“Our third-quarter results were strong, as we continue to make progress heading into
2025 and beyond," said Robert M. Davis, chairman and chief executive officer, Merck. "Our
pipeline is advancing and expanding, demonstrating our success in creating a sustainable
innovation engine, and positioning Merck with a more diversified portfolio to drive growth. I
continue to remain confident in the strength of our business and our ability to execute, and I

-- 1 of 14 --

- 2 -
want to thank our colleagues across the globe for their focus and commitment as we work to
create lasting value for patients, shareholders and all our stakeholders.”
Financial Summary
$ in millions, except EPS amounts
Third Quarter
2024 2023 Change
Change Ex-
Exchange
Sales $16,657 $15,962 4% 7%
GAAP net income1 3,157 4,745 -33% -30%
Non-GAAP net income that excludes certain items1,2* 3,985 5,427 -27% -23%
GAAP EPS 1.24 1.86 -33% -30%
Non-GAAP EPS that excludes certain items2* 1.57 2.13 -26% -23%
*Refer to table on page 7.
In the third quarter of 2024, total worldwide sales were $16.7 billion, an increase of 4%
compared with the third quarter of 2023; excluding the impact of foreign exchange, growth was
7%. Sales growth in the third quarter of 2024 was primarily due to increased usage of
KEYTRUDA globally, contributions from new launches, including WINREVAIR and
CAPVAXIVE, and strong growth in Merck’s Animal Health business. Revenue growth in the third
quarter of 2024 was partially offset by lower sales of JANUVIA and JANUMET, lower combined
sales of GARDASIL/GARDASIL 9 and lower sales of LAGEVRIO. Third-quarter
GARDASIL/GARDASIL 9 sales declined year-over-year due to reduced demand in China;
outside of China, the company achieved double-digit sales growth for GARDASIL/GARDASIL 9
in almost every major region globally.
For the third quarter of 2024, Generally Accepted Accounting Principles (GAAP)
earnings per share (EPS) assuming dilution was $1.24 and non-GAAP EPS was $1.57. The
declines in GAAP and Non-GAAP EPS in the third quarter of 2024 versus the prior year were
largely due to a net charge of $0.79 per share in the aggregate for the acquisition of Eyebiotech
Limited (EyeBio) and a related development milestone, the acquisition of CN201 (now known as
MK-1045) from Curon Biopharmaceutical (Curon), as well as a payment received from Daiichi
Sankyo related to the expansion of the existing development and commercialization agreement.
There were no significant business development transaction charges in the third quarter of
2023.
Non-GAAP EPS in both periods excludes acquisition- and divestiture-related costs,
costs related to restructuring programs, as well as income and losses from investments in equity
securities.
1 Net income attributable to Merck & Co., Inc.
2 Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s
compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but
not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP
adjustments, see Table 2a attached to this release.

-- 2 of 14 --

- 3 -
Year-to-date results can be found in the attached tables.
Third-Quarter Sales Performance
The following table reflects sales of the company’s top products and significant
performance drivers.
Third Quarter
$ in millions 2024 2023 Change
Change
Ex-
Exchange Commentary
Total Sales $16,657 $15,962 4% 7%
Approximately 2 percentage points of the
negative impact of foreign exchange was due
to devaluation of Argentine peso, which was
largely offset by inflation-related price
increases, consistent with practice in that
market.
Pharmaceutical 14,943 14,263 5% 8%
Increase driven by growth in oncology and
cardiovascular, partially offset by declines in
diabetes, vaccines and virology.
KEYTRUDA 7,429 6,338 17% 21%
Growth driven by increased global uptake in
earlier-stage indications, including triple-
negative breast cancer (TNBC), renal cell
carcinoma (RCC) and non-small cell lung
cancer (NSCLC), as well as continued strong
global demand from metastatic indications.
Approximately 3 percentage points of the
negative impact of foreign exchange was due
to devaluation of Argentine peso, which was
largely offset by inflation-related price
increases.
GARDASIL/
GARDASIL 9 2,306 2,585 -11% -10%
Decline primarily due to lower demand in
China compared with prior year, partially offset
by higher sales in the U.S., driven by public-
sector buying patterns, higher pricing and
demand, as well as higher demand in most
international regions.
PROQUAD, M-M-R II
and VARIVAX 703 713 -1% -1%
Decline primarily due to timing of shipments
and lower tenders in Latin America, largely
offset by higher demand in certain international
markets.
JANUVIA/JANUMET 482 835 -42% -38%
Decline primarily due to lower pricing in the
U.S., as well as ongoing generic competition in
many international markets.
BRIDION 420 424 -1% 0%
Relatively flat compared with prior year due to
generic competition in certain international
markets, particularly in Europe and Japan,
largely offset by higher demand and pricing in
the U.S.
LAGEVRIO 383 640 -40% -36%
Decline primarily due to lower demand in
Japan, partially offset by uptake from
commercial launch in the U.S.
Lynparza* 337 299 13% 13% Growth primarily due to higher global demand.
Lenvima* 251 260 -3% -4%
Decline primarily due to timing of shipments in
China in the prior year, partially offset by
higher demand in the U.S.

-- 3 of 14 --

- 4 -
VAXNEUVANCE 239 214 12% 13%
Growth largely driven by continued uptake
from launches in Europe and Japan, partially
offset by lower demand in the U.S. due to
competition.
PREVYMIS 208 157 32% 36%
Growth primarily due to higher global demand,
particularly in the U.S.
ROTATEQ 193 156 24% 25%
Growth primarily due to public-sector buying
patterns in the U.S. and timing of shipments in
China.
WINREVAIR 149 - - -
Represents continued uptake since launch in
the U.S. in the second quarter.
WELIREG 139 54 156% 157%
Growth primarily driven by higher demand in
the U.S., largely attributable to ongoing uptake
of a new indication.
Animal Health 1,487 1,400 6% 11%
Growth primarily driven by higher demand and
pricing for both Companion Animal and
Livestock product portfolios, as well as sales
related to July 2024 acquisition of Elanco aqua
business. Approximately 2 percentage points
of the negative impact of foreign exchange
was due to devaluation of Argentine peso,
which was largely offset by inflation-related
price increases.
Livestock 886 874 1% 7%
Growth primarily driven by higher pricing and
higher demand for poultry and swine products,
as well as sales related to acquisition of
Elanco aqua business.
Companion Animal 601 526 14% 17%
Growth primarily driven by uptake from new
product launches, including the injectable
formulation of BRAVECTO in certain
international markets, as well as higher pricing
across product portfolio. Sales of BRAVECTO
were $266 million and $235 million in current
and prior year quarters, respectively, which
represented growth of 13%, or 16% excluding
impact of foreign exchange.
Other Revenues** 227 299 -24% -22%
Decline primarily due to lower payments
received for out-licensing arrangements and
lower royalty income.
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization
costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.

-- 4 of 14 --

- 5 -
Third-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP2
Third Quarter 2024
Cost of sales $4,080 $639 $192 $- $3,249
Selling, general and administrative 2,731 43 31 - 2,657
Research and development 5,862 24 - - 5,838
Restructuring costs 56 - 56 - -
Other (income) expense, net (162) (27) - 58 (193)
Third Quarter 2023
Cost of sales $4,264 $552 $33 $- $3,679
Selling, general and administrative 2,519 17 40 - 2,462
Research and development 3,307 10 - - 3,297
Restructuring costs 126 - 126 - -
Other (income) expense, net 126 (24) - 17 133
GAAP Expense, EPS and Related Information
Gross margin was 75.5% for the third quarter of 2024 compared with 73.3% for the third
quarter of 2023. The increase was primarily due to the favorable impact of product mix
(including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9), partially
offset by higher restructuring costs (primarily reflecting asset impairment charges), as well as
higher amortization of intangible assets.
Selling, general and administrative (SG&A) expenses were $2.7 billion in the third
quarter of 2024, an increase of 8% compared with the third quarter of 2023. The increase was
primarily due to higher administrative, promotional, selling, and acquisition-related costs,
partially offset by the favorable impact of foreign exchange.
Research and development (R&D) expenses were $5.9 billion in the third quarter of
2024, an increase of 77% compared with the third quarter of 2023. The increase was primarily
due to a charge of $1.35 billion for the acquisition of EyeBio and a $100 million charge for a
related development milestone, as well as a charge of $750 million to acquire CN201 (MK-1045)
from Curon. The increase in R&D expenses was also driven by higher compensation and
benefit costs, as well as higher clinical development spending. The increase in R&D expenses
was partially offset by the favorable impact of foreign exchange.
Other (income) expense, net, was $162 million of income in the third quarter of 2024
compared with $126 million of expense in the third quarter of 2023. The favorability was
primarily due to a $170 million payment received from Daiichi Sankyo related to the expansion
3 Reflects expenses related to acquisitions of businesses, including the amortization of intangible assets, intangible asset
impairment charges and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations and licensing arrangements.

-- 5 of 14 --

- 6 -
of the existing development and commercialization agreement, lower exchange losses and
lower net interest expense.
The effective tax rate of 22.7% for the third quarter of 2024 includes a 7.2 percentage
point combined unfavorable impact related to the EyeBio and Curon transactions.
GAAP EPS was $1.24 for the third quarter of 2024 compared with $1.86 for the third
quarter of 2023. GAAP EPS in the third quarter of 2024 includes a net charge of $0.79 per
share in the aggregate for the EyeBio, Curon and Daiichi Sankyo transactions. There were no
significant business development transaction charges in the third quarter of 2023.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 80.5% for the third quarter of 2024 compared with 77.0%
for the third quarter of 2023. The increase was primarily due to the favorable impact of product
mix (including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9).
Non-GAAP SG&A expenses were $2.7 billion in the third quarter of 2024, an increase of
8% compared with the third quarter of 2023. The increase was primarily due to higher
administrative, promotional and selling costs, partially offset by the favorable impact of foreign
exchange.
Non-GAAP R&D expenses were $5.8 billion in the third quarter of 2024, an increase of
77% compared with the third quarter of 2023. The increase was primarily due to a charge of
$1.35 billion for the acquisition of EyeBio and a $100 million charge for a related development
milestone, as well as a charge of $750 million to acquire CN201 (MK-1045) from Curon. The
increase in R&D expenses was also driven by higher compensation and benefit costs, as well
as higher clinical development spending. The increase in R&D expenses was partially offset by
the favorable impact of foreign exchange.
Non-GAAP other (income) expense, net, was $193 million of income in the third quarter
of 2024 compared with $133 million of expense in the third quarter of 2023. The favorability was
primarily due to a $170 million payment received from Daiichi Sankyo related to the expansion
of the existing development and commercialization agreement, lower exchange losses and
lower net interest expense.
The non-GAAP effective tax rate of 21.9% for the third quarter of 2024 includes a 6.0
percentage point combined unfavorable impact related to the EyeBio and Curon transactions.
Non-GAAP EPS was $1.57 for the third quarter of 2024 compared with $2.13 for the
third quarter of 2023. Non-GAAP EPS in the third quarter of 2024 includes a net charge of $0.79
per share in the aggregate for the EyeBio, Curon and Daiichi Sankyo transactions. There were
no significant business development transaction charges in the third quarter of 2023.

-- 6 of 14 --

- 7 -
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
Pipeline and Portfolio Highlights
In the third quarter, Merck continued to develop and augment its strong, diverse pipeline
and achieve key regulatory and clinical milestones.
In cardiovascular disease, Merck continued to build on positive momentum in its U.S.
launch of WINREVAIR. As of the end of September 2024, more than 3,700 patients have been
prescribed WINREVAIR. The company also received the European Commission’s (EC)
approval of WINREVAIR, in combination with other pulmonary arterial hypertension (PAH)
therapies, for the treatment of adult patients with PAH with World Health Organization (WHO)
functional Class II to III. WINREVAIR is the first activin signaling inhibitor approved for the
treatment of PAH in Europe. WINREVAIR has launched in Germany and Merck is working to
obtain reimbursement for WINREVAIR in other countries in the EU, which should occur in most
other major European markets in the second half of 2025.
In oncology, Merck continued to reinforce its leadership in women’s and earlier stages of
cancers and demonstrate progress in its research pipeline. At the European Society for Medical
Oncology (ESMO) Congress 2024, three of the company’s data presentations were highlighted
during Presidential Symposium sessions. These included overall survival (OS) data from the
Phase 3 KEYNOTE-522 trial in high-risk, early-stage TNBC and from the Phase 3 KEYNOTE-
A18 trial (also known as ENGOT-cx11/GOG-3047) in high-risk, locally advanced cervical
cancer. In addition, new positive data on investigational candidates from Merck’s pipeline were
presented, including for patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate (ADC)
being developed in collaboration with Daiichi Sankyo, and for sacituzumab tirumotecan (sac-
TMT), an anti-TROP2 ADC being developed in collaboration with Kelun-Biotech.
The company also achieved several regulatory milestones, including new approvals for
KEYTRUDA-based regimens in the U.S., Europe and Japan. In addition, Merck recently
Third Quarter
$ in millions, except EPS amounts 2024 2023
EPS
GAAP EPS $1.24 $1.86
Difference 0.33 0.27
Non-GAAP EPS that excludes items listed below2 $1.57 $2.13
Net Income
GAAP net income1 $3,157 $4,745
Difference 828 682
Non-GAAP net income that excludes items listed below1,2 $3,985 $5,427
Excluded Items:
Acquisition- and divestiture-related costs3 $679 $555
Restructuring costs 279 199
Loss from investments in equity securities 58 17
Decrease to net income 1,016 771
Estimated income tax (benefit) expense (188) (89)
Decrease to net income $828 $682

-- 7 of 14 --

- 8 -
announced top-line results from the KEYNOTE-689 trial, which marks the first positive trial in
two decades for patients with resected, locally advanced head and neck squamous cell
carcinoma (LA-HNSCC).
In vaccines, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted in
October 2024 to recommend CAPVAXIVE for individuals 50 to 64 years of age. This decision
expanded upon the initial unanimous recommendation in June 2024 for use of CAPVAXIVE in
adults age 65 and older, among other cohorts.
At IDWeek 2024, Merck presented positive results from the Phase 2b/3 trial of
clesrovimab (MK-1654), an investigational respiratory syncytial virus (RSV) preventative
monoclonal antibody for infants. These results support the potential for clesrovimab to become
the first and only single-dose immunization designed to protect infants with the same dose,
regardless of weight, for the duration of their first RSV season (six months).
In immunology, long-term efficacy and safety data for tulisokibart (MK-7240), an
investigational humanized monoclonal antibody directed to a novel target, tumor necrosis factor
(TNF)-like cytokine 1A (TL1A), from the Phase 2 ARTEMIS-UC and APOLLO-CD studies in
ulcerative colitis (UC) and Crohn’s disease (CD), were presented at the United European
Gastroenterology (UEG) Week 2024 Congress. Both studies showed that, at week 50,
maintenance of treatment efficacy was generally observed in 12-week induction responders.
Phase 3 studies in UC and CD are ongoing.
In addition, Merck continued to expand and diversify its pipeline by securing strategic
business development opportunities. Merck completed its acquisition of CN201 (MK-1045), a
next-generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies
and autoimmune diseases, from Curon. Merck also announced the expansion of the global
development and commercialization agreement with Daiichi Sankyo to include MK-6070, an
investigational delta-like ligand 3 (DLL3) targeting T-cell engager. The companies are planning
to evaluate MK-6070 in combination with ifinatamab deruxtecan (I-DXd) in certain patients with
small cell lung cancer (SCLC), as well as other potential combinations.

-- 8 of 14 --

- 9 -
Notable recent news releases on Merck’s pipeline and portfolio are provided in the table
that follows.
Oncology
FDA Approved KEYTRUDA Plus Pemetrexed and Platinum
Chemotherapy as First-Line Treatment for Adult Patients With
Unresectable Advanced or Metastatic Malignant Pleural
Mesothelioma, Based on Results From Phase 3 KEYNOTE-
483/CCTG IND.227 Trial
(Read
Announcement)
EC Approved KEYTRUDA Plus Padcev as First-Line Treatment
of Unresectable or Metastatic Urothelial Carcinoma in Adults,
Based on Results From Phase 3 KEYNOTE-A39/EV-302 Trial
(Read
Announcement)
KEYTRUDA Received 30th Approval From EC With Two New
Indications in Gynecologic Cancers, Based on Results From
Phase 3 KEYNOTE-868/NRG-GY018 and KEYNOTE-A18 Trials
(Read
Announcement)
KEYTRUDA Received New Approvals in Japan for Certain
Patients With NSCLC, Based on Results From Phase 3
KEYNOTE-671 Trial, and for Radically Unresectable Urothelial
Carcinoma, Based on Results From Phase 3 KEYNOTE-
A39/EV-302 and Phase 2 KEYNOTE-052 Trials
(Read
Announcement)
KEYTRUDA Plus Chemotherapy Before Surgery and Continued
as Single Agent After Surgery Reduced Risk of Death by More
Than One-Third (34%) Versus Neoadjuvant Chemotherapy in
High-Risk, Early-Stage TNBC, Based on Results From Phase 3
KEYNOTE-522
(Read
Announcement)
KEYTRUDA Plus Chemoradiotherapy (CRT) Reduced Risk of
Death by 33% Versus CRT Alone in Patients With Newly
Diagnosed, High-Risk, Locally Advanced Cervical Cancer, Based
on Results From Phase 3 KEYNOTE-A18/ENGOT-cx11/GOG-
3047 Trial
(Read
Announcement)
KEYTRUDA Ten-Year Data Demonstrated Sustained OS Benefit
Versus Ipilimumab in Advanced Melanoma, Based on Results
From Phase 3 KEYNOTE-006 Trial
(Read
Announcement)
KEYTRUDA Plus Lenvima in Combination With Transarterial
Chemoembolization (TACE) Significantly Improved Progression-
Free Survival Compared to TACE Alone in Patients With
Unresectable, Non-Metastatic Hepatocellular Carcinoma, Based
on Results From Phase 3 LEAP-012 Trial
(Read
Announcement)
KEYTRUDA Plus Trastuzumab and Chemotherapy Significantly
Improved OS Versus Trastuzumab and Chemotherapy Alone in
First-Line Treatment of Patients With HER2-Positive Advanced
Gastric or GEJ Adenocarcinoma, Based on Results From Phase
3 KEYNOTE-811 Trial
(Read
Announcement)
KEYTRUDA Met Primary Endpoint of Event-Free Survival as
Perioperative Treatment Regimen in Patients With Resected, LA-
HNSCC, Based on Results From Phase 3 KEYNOTE-689 Trial
(Read
Announcement)
Patritumab Deruxtecan (HER3-DXd) Demonstrated Statistically
Significant Improvement in Progression-Free Survival Versus
Doublet Chemotherapy in Patients With Locally Advanced or
Metastatic EGFR-Mutated NSCLC, Based on Results From
Phase 3 HERTHENA-Lung02 Trial
(Read
Announcement)
Ifinatamab Deruxtecan Continued to Demonstrate Promising
Objective Response Rates in Patients With Extensive-Stage
SCLC, Based on Results From Phase 2 IDeate-Lung01 Trial
(Read
Announcement)
Merck and Moderna Initiated Phase 3 Trial Evaluating Adjuvant
V940 (mRNA-4157) in Combination With KEYTRUDA After
Neoadjuvant KEYTRUDA and Chemotherapy in Patients With
Certain Types of NSCLC
(Read
Announcement)
Merck Initiated Phase 3 Shorespan-007 Trial for Bomedemstat,
an Investigational Candidate for the Treatment of Certain
Patients With Essential Thrombocythemia
(Read
Announcement)

-- 9 of 14 --

- 10 -
Merck and Daiichi Sankyo Initiated Phase 3 IDeate-Lung02 Trial
of Ifinatamab Deruxtecan in Patients With Relapsed SCLC
(Read
Announcement)
Merck and Exelixis Signed Clinical Development Collaboration
To Evaluate Investigational Zanzalintinib in Combination With
KEYTRUDA in Head and Neck Cancer and in Combination With
WELIREG in RCC
(Read
Announcement)
Vaccines
Clesrovimab (MK-1654), an Investigational RSV Preventative
Monoclonal Antibody, Significantly Reduced Incidence of RSV
Disease and Hospitalization in Healthy Preterm and Full-Term
Infants, Based on Results From Phase 2b/3 MK-1654-004 Trial
(Read
Announcement)
CDC’s ACIP Recommended CAPVAXIVE for Pneumococcal
Vaccination in Adults 50 Years of Age and Older
(Read
Announcement)
CAPVAXIVE Demonstrated Positive Immune Responses in
Adults With Increased Risk for Pneumococcal Disease, Based
on Results From Phase 3 STRIDE-8 Trial
(Read
Announcement)
Merck Announced Positive Top-line Results From Phase 3 Trial
Evaluating Efficacy and Safety of GARDASIL 9 in Japanese
Males
(Read
Announcement)
Cardiovascular
EC Approved WINREVAIR in Combination With Other PAH
Therapies for the Treatment of PAH in Adult Patients With
Functional Class II-III, Based on Results From Phase 3
STELLAR Trial
(Read
Announcement)
Immunology
Merck Presented New Long-Term Data for Tulisokibart (MK-
7240), an Investigational Anti-TL1A Monoclonal Antibody, in
Inflammatory Bowel Disease at UEG Week 2024
(Read
Announcement)
Infectious Diseases
Merck and Gilead Announced Phase 2 Data Showing a
Treatment Switch to an Investigational Oral Once-Weekly
Combination Regimen of Islatravir and Lenacapavir (MK-8591D)
Maintained Viral Suppression in Adults at Week 48
(Read
Announcement)
Ophthalmology Merck and EyeBio Initiated Phase 2b/3 Clinical Trial for MK-3000
for the Treatment of Diabetic Macular Edema
(Read
Announcement)
Sustainability Highlights
Merck issued its 2023/2024 Impact Report, reaffirming its commitment to operating
responsibly and enabling broad access to its products. The report noted how the company
reached more than 550 million people around the world with its medicines and vaccines through
commercial channels, clinical trials, voluntary licensing and product donations.
Full-Year 2024 Financial Outlook
The following table summarizes the company’s full-year financial outlook.
Full Year 2024
Updated Prior
Sales* $63.6 to $64.1 billion $63.4 to $64.4 billion
Non-GAAP Gross margin2 Approximately 81% Approximately 81%
Non-GAAP Operating expenses2** $27.8 to $28.3 billion $26.8 to $27.6 billion
Non-GAAP Other (income) expense, net2 Approximately $100 million expense Approximately $350 million expense
Non-GAAP Effective tax rate2 16.0% to 17.0% 15.5% to 16.5%
Non-GAAP EPS2*** $7.72 to $7.77 $7.94 to $8.04
Share count (assuming dilution) Approximately 2.54 billion Approximately 2.54 billion
*The company does not have any non-GAAP adjustments to sales.
**Includes one-time R&D charges of $656 million for Harpoon Therapeutics, Inc. (Harpoon) acquisition, $1.45 billion for EyeBio acquisition
and related development milestone payment, and $750 million for acquisition of CN201 (MK-1045) from Curon. Outlook does not assume
any additional significant potential business development transactions.
***Includes net one-time charge of $1.05 per share in aggregate for the Harpoon, EyeBio and Curon transactions, and the cash payment
received from Daiichi Sankyo.

-- 10 of 14 --

- 11 -
Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-
GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax
rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot
predict with reasonable certainty the amounts necessary for such a reconciliation, including
intangible asset impairment charges, legal settlements, and gains and losses from investments
in equity securities either owned directly or through ownership interests in investment funds,
without unreasonable effort. These items are inherently difficult to forecast and could have a
significant impact on the company’s future GAAP results.
Merck continues to experience strong growth, including from KEYTRUDA, new product
launches and Animal Health. As a result, Merck is narrowing the range of its full-year sales
outlook.
Merck now expects its full-year sales to be between $63.6 billion and $64.1 billion,
including a negative impact of foreign exchange of approximately 3 percentage points, at mid-
October 2024 exchange rates. Approximately 2 percentage points of the negative impact of
foreign exchange is due to the devaluation of the Argentine peso, which is being largely offset
by inflation-related price increases, consistent with practice in that market.
Merck now expects its full-year non-GAAP effective income tax rate to be between
16.0% and 17.0%, which includes an unfavorable impact related to the one-time charge
associated with the acquisition of CN201 (MK-1045) from Curon.
Merck now expects its full-year non-GAAP EPS to be between $7.72 and $7.77. The
outlook includes a negative impact of foreign exchange of approximately $0.30 per share. The
negative impact of foreign exchange is primarily due to the devaluation of the Argentine peso,
which is being largely offset by inflation-related price increases, consistent with practice in that
market. This revised non-GAAP EPS range reflects a net charge of $0.24 per share for the
following items not previously included in the outlook:
• The acquisition of CN201 (MK-1045) from Curon.
• Payment received from Daiichi Sankyo related to the expansion of the existing
development and commercialization agreement.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to
restructuring programs, income and losses from investments in equity securities, as well as a
tax benefit in 2024 due to a reduction in reserves for unrecognized income tax benefits,
resulting from the expiration of the statute of limitations for assessments related to the 2019
federal tax return year.

-- 11 of 14 --

- 12 -
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the
earnings conference call on Thursday, October 31, at 9 a.m. ET via this weblink. A replay of the
webcast, along with the sales and earnings news release, supplemental financial disclosures,
and slides highlighting the results, will be available at www.merck.com.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free)
or (517) 308-9448 and using the access code 9818590.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us on X (formerly
Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.

-- 12 of 14 --

- 13 -
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site ( www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
VERQUVO (vericiguat)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: Investor Contacts:
Robert Josephson
(203) 914-2372
robert.josephson@merck.com
Peter Dannenbaum
(732) 594-1579
peter.dannenbaum@merck.com

-- 13 of 14 --

- 14 -
Michael Levey
(215) 872-1462
michael.levey@merck.com
Steven Graziano
(732) 594-1583
steven.graziano@merck.com

-- 14 of 14 --